» Authors » Paul Lephart

Paul Lephart

Explore the profile of Paul Lephart including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 1003
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Hansen Z, Cha W, Nohomovich B, Newton D, Lephart P, Salimnia H, et al.
Sci Rep . 2021 Nov; 11(1):22368. PMID: 34785751
Campylobacter commonly causes foodborne infections and antibiotic resistance is an imminent concern. It is not clear, however, if the human gut 'resistome' is affected by Campylobacter during infection. Application of...
2.
Lephart P, LeBar W, Newton D
Infect Dis Clin North Am . 2021 Aug; 35(3):789-802. PMID: 34362544
A great clinical microbiology laboratory supporting a great infection prevention program requires focusing on the following services: rapid and accurate identification of pathogens associated with health care-associated infections; asymptomatic surveillance...
3.
Rodrigues J, Cha W, Mosci R, Mukherjee S, Newton D, Lephart P, et al.
Front Public Health . 2021 Jul; 9:672473. PMID: 34262891
is the leading cause of bacterial gastroenteritis and antibiotic resistant are a serious threat to public health. Herein, we sought to evaluate trends in infections, quantify resistance frequencies, and identify...
4.
Kaul D, Valesano A, Petrie J, Sagana R, Lyu D, Lin J, et al.
Am J Transplant . 2021 Feb; 21(8):2885-2889. PMID: 33565705
We describe a case of proven transmission of SARS-CoV-2 from lung donor to recipient. The donor had no clinical history or findings suggestive of infection with SARS-CoV-2 and tested negative...
5.
Cwengros L, Mynatt R, Timbrook T, Mitchell R, Salimnia H, Lephart P, et al.
Open Forum Infect Dis . 2020 Sep; 7(8):ofaa278. PMID: 32875001
Background: Bloodstream infections (BSIs) due to ceftriaxone (CRO)-resistant Enterobacteriaceae are associated with delays in time to appropriate therapy and worse outcomes compared with infections due to susceptible isolates. However, treating...
6.
Mukherjee S, Anderson C, Mosci R, Newton D, Lephart P, Salimnia H, et al.
Front Med (Lausanne) . 2019 Nov; 6:250. PMID: 31781566
Non-typhoidal (NTS) are important enteric pathogens causing over 1 million foodborne illnesses in the U.S. annually. The widespread emergence of antibiotic resistance in NTS isolates has limited the availability of...
7.
Mashock M, Faron M, Carroll K, Dang C, Lewis S, Salimnia H, et al.
J Clin Microbiol . 2019 Nov; 58(2). PMID: 31776191
is the leading cause of diarrhea in hospitalized U.S. patients and results in over 400,000 cases of infection per year. infections have mortality rates of 6 to 30% and significantly...
8.
Henig O, Cooper C, Kaye K, Lephart P, Salimnia H, Taylor M, et al.
J Antimicrob Chemother . 2019 Jan; 74(Suppl 1):i32-i39. PMID: 30690538
Background: Rapid organism identification and antimicrobial susceptibility testing (AST) can optimize antimicrobial therapy in patients with bacteraemia. The Accelerate Pheno™ system (ACC) can provide identification and AST results within 7 ...
9.
Henig O, Kaye K, Chandramohan S, Cooper C, Lephart P, Salimnia H, et al.
Antimicrob Agents Chemother . 2018 Dec; 63(3). PMID: 30559141
Strategies are needed to improve time to optimal therapy in patients with bloodstream infections (BSI) due to resistant Gram-negative (GN) pathogens. Accelerate Pheno (ACC) can provide antimicrobial susceptibility results within...
10.
Pogue J, Heil E, Lephart P, Johnson J, Mynatt R, Salimnia H, et al.
Antimicrob Agents Chemother . 2018 Feb; 62(5). PMID: 29483115
Rapid diagnostic tests (RDTs) have revolutionized the management of Gram-negative bacteremia by allowing antimicrobial stewardship teams the ability to escalate therapy and improve patient outcomes through timely organism identification and...